@Article{Czech2009,
journal="Przewodnik Lekarza/Guide for GPs",
issn="1505-8409",
year="2009",
title="Incretin mimetics and drugs increasing the level of endogenous incretins in the treatment of type 2 diabetes mellitus",
abstract="The term incretins relates to the following intestinal hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). They are responsible for 50-60% of insulin secretion. In type 2 diabetes the secretion of these hormones is diminished.  In order to treat such disorders in type 2 diabetes, analogues of GLP-1 acting analogously as endogenous GLP-1 and drugs inhibiting the activity of DPP-IV (dipeptidyl peptidase IV) are introduced. In the treatment of type 2 diabetes these drugs are used as a monotherapy or a combined therapy either with metformin or sulfonylureas.",
author="Czech, Anna",
pages="48--53",
url="https://www.termedia.pl/Incretin-mimetics-and-drugs-increasing-the-level-of-endogenous-incretins-in-the-treatment-of-type-2-diabetes-mellitus,8,12845,1,1.html"
}